|
|
Prepublished online as a Blood First Edition Paper on April 10, 2003; DOI 10.1182/blood-2003-01-0182.
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2003, Vol. 102, No. 3, pp. 1057-1063
NEOPLASIA
Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia
Wendelina J. M. Mackus,
Florine N. J. Frakking,
Annette Grummels,
Laila E. Gamadia,
Godelieve J. de Bree,
Dörte Hamann,
René A. W. van Lier, and
Marinus H. J. van Oers
From the Department of Hematology, Academic Medical Center, Laboratory for Experimental Immunology, Academic Medical Center, University of Amsterdam, The Netherlands
In patients with B-cell chronic lymphocytic leukemia (B-CLL), the absolute number of T cells is increased. Although it has been suggested that these T cells might be tumor specific, concrete evidence for this hypothesis is lacking. We performed a detailed immunophenotypic analysis of the T-cell compartment in the peripheral blood of 28 patients with B-CLL (Rai 0, n = 12; Rai I-II, n = 10; Rai III-IV, n = 6) and 12 healthy age-matched controls and measured the ability of these patients to mount specific immune responses. In all Rai stages a significant increase in the absolute numbers of CD3+ cells was observed. Whereas the number of CD4+ cells was not different from controls, patients with B-CLL showed significantly increased relative and absolute numbers of CD8+ cells, which exhibited a CD45RA+CD27- cytotoxic phenotype. Analysis of specific immune responses with tetrameric cytomegalovirus (CMV)–peptide complexes showed that patients with B-CLL had significantly increased numbers of tetramer-binding CMV-specific CD8+ T cells. The rise in the total number of CD8+ cytotoxic T cells was evident only in CMV-seropositive B-CLL patients. Thus, our data suggest that in patients with B-CLL the composition of T cells is shifted toward a CD8+ cytotoxic cell type in an effort to control infections with persistent viruses such as CMV. Moreover, they offer an explanation for the high incidence of CMV reactivation in CLL patients treated with T cell–depleting agents, such as the monoclonal antibody (mAb) alemtuzumab (Campath;  -CD52 mAb). Furthermore, because in CMV-seronegative patients no increase in cytotoxic CD8+ T cells is found, our studies do not support the hypothesis that tumor-specific T cells account for T-cell expansion in B-CLL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. D. Hamblin and T. J. Hamblin
The immunodeficiency of chronic lymphocytic leukaemia
Br. Med. Bull.,
September 1, 2008;
87(1):
49 - 62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O'Brien, F. Ravandi, T. Riehl, W. Wierda, X. Huang, J. Tarrand, B. O'Neal, H. Kantarjian, and M. Keating
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
Blood,
February 15, 2008;
111(4):
1816 - 1819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Dearden
Disease-Specific Complications of Chronic Lymphocytic Leukemia
Hematology,
January 1, 2008;
2008(1):
450 - 456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Kater, M. H. J. van Oers, and T. J. Kipps
Cellular immune therapy for chronic lymphocytic leukemia
Blood,
October 15, 2007;
110(8):
2811 - 2818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. N. Potter, C. I. Mockridge, L. Neville, I. Wheatley, M. Schenk, J. Orchard, A. S. Duncombe, G. Packham, and F. K. Stevenson
Structural and Functional Features of the B-Cell Receptor in IgG-Positive Chronic Lymphocytic Leukemia.
Clin. Cancer Res.,
March 15, 2006;
12(6):
1672 - 1679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mous, P. S. Savage, E. B. Remmerswaal, R. A.W. van Lier, E. Eldering, and M. H.J. Van Oers
Redirection of CMV Specific CTL towards B-CLL Via CD20 Targeted HLA/CMV Complexes.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
449 - 449.
[Abstract]
|
|
|
|
|
|
|
E. M. M. van Leeuwen, G. J. de Bree, E. B. M. Remmerswaal, S.-L. Yong, K. Tesselaar, I. J. M. t. Berge, and R. A. W. van Lier
IL-7 receptor {alpha} chain expression distinguishes functional subsets of virus-specific human CD8+ T cells
Blood,
September 15, 2005;
106(6):
2091 - 2098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bonyhadi, M. Frohlich, A. Rasmussen, C. Ferrand, L. Grosmaire, E. Robinet, J. Leis, R. T. Maziarz, P. Tiberghien, and R. J. Berenson
In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia
J. Immunol.,
February 15, 2005;
174(4):
2366 - 2375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. M. van Leeuwen, E. B. M. Remmerswaal, M. T. M. Vossen, A. T. Rowshani, P. M. E. Wertheim-van Dillen, R. A. W. van Lier, and I. J. M. ten Berge
Emergence of a CD4+CD28- Granzyme B+, Cytomegalovirus-Specific T Cell Subset after Recovery of Primary Cytomegalovirus Infection
J. Immunol.,
August 1, 2004;
173(3):
1834 - 1841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. K. Stevenson and F. Caligaris-Cappio
Chronic lymphocytic leukemia: revelations from the B-cell receptor
Blood,
June 15, 2004;
103(12):
4389 - 4395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Gamadia, E. M. M. van Leeuwen, E. B. M. Remmerswaal, S.-L. Yong, S. Surachno, P. M. E. Wertheim-van Dillen, I. J. M. ten Berge, and R. A. W. van Lier
The Size and Phenotype of Virus-Specific T Cell Populations Is Determined by Repetitive Antigenic Stimulation and Environmental Cytokines
J. Immunol.,
May 15, 2004;
172(10):
6107 - 6114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
